Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Nov 26, 2019 11:07am
83 Views
Post# 30393414

RE:RE:RE:RE:RE:Replicel

RE:RE:RE:RE:RE:Replicel
Ingiboy wrote: I was expecting a little more detail on this ongoing dispute with Shiseido.  As usual more vagueness.  
"RepliCel is now actively engaging Shiseido to deliver the study data and reach a resolution to the dispute between the parties."
 The question is what is the dispute about....still no answer.  They state at the moment there will be no litigation or arbitration.
The rest of the NR is encouraging although I would like a little more detail on when they will apply for CE Mark Approval and how long the process takes.  Also how long do they intend to test the device before sending it for approval.  Simply saying 2020 is again too vague.





Vagueness is Bucklers middle name. I did a little research a couple years ago when replicel first started talking about the CE mark. If memory serves correct it is 6-8 weeks(barring any issues)
Bullboard Posts